Glutamate Emotion Memory Study

NCT ID: NCT05809609

Last Updated: 2024-05-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-01
• Study Completion Date: 2024-12-28

Brief Summary

Clinical depression often includes a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or looking forward to things. A licensed drug called ketamine affects the levels of glutamate, a chemical messenger in the brain, and has been used as a treatment particularly for depression which hasn't got better with other types of medication. Glutamate plays a role in learning and memory so the investigators are interested in understanding how ketamine can affect how people with depression remember past negative and positive memories and how they experience reward.

The investigators are conducting a study in depressed participants who did not improve with the standard antidepressant treatment to expand our understanding on how ketamine can influence memory, the way people understand emotions and learn from rewards and punishments. Study participants will undergo medical and psychiatric health screening, drug administration (ketamine or saline), questionnaires and computer tasks before and after the administration of the study drug, and an MRI scan after administration of the drug. MRI is a type of brain scan that allows us to see how the brain responds during for example memories of things which have happened in the past. This project will help us understand how NMDA antagonists may work in depression.

Detailed Description

Questions regarding the exact molecular mechanisms of ketamine and its effects on the brain circuitry and networks for the treatment of clinical depression remain largely unanswered. Thus, in the present study the investigators aim to elucidate the effect of ketamine on 1) reconsolidation of autobiographical memories, 2) connectivity of brain circuits involved in autobiographical memories, 3) measures of emotional processing, reward processing and emotional memory in patients suffering from treatment resistant depression. The ultimate goal of this project is to elucidate the antidepressant mechanisms of action of ketamine to facilitate the development of rapid acting antidepressants targeting the glutamatergic system.

Conditions

Treatment Resistant Depression; Depression; Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Ketamine

Participants in this arm will receive a single intravenous injection, antidepressant dose of Ketamine hydrochloride (0.5mg/kg)

Group Type: EXPERIMENTAL

Ketamine Hydrochloride

Intervention Type: DRUG

Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.

Placebo

Participants in this arm will receive a single intravenous injection of an inactive placebo (0.9% sodium chloride)

Group Type: PLACEBO_COMPARATOR

No intervention (placebo)

Intervention Type: OTHER

Placebo injection (0.9% sodium chloride)

Interventions

Ketamine Hydrochloride

Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.

Intervention Type: DRUG

No intervention (placebo)

Placebo injection (0.9% sodium chloride)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Willing and able to give informed consent for participation in the study
• Sufficiently fluent English to understand and complete the tasks
• Registered with a GP and consents to GP being informed of participation in the study

Participants need to meet a number of concurrent clinical criteria:

• Current criteria for Major Depressive Disorder, in a current major depressive episode as determined by the SCID-5.
• Inadequate response to at least one and no more than three antidepressant treatments.
• Currently taking a licensed antidepressant at a therapeutic dose for at least four weeks.
• Pre-menopausal women and male participants engaging in sex with a risk of pregnancy must agree to use a highly effective method of contraception from Screening Visit until 30 days after receiving the study medication treatment.

Acceptable methods of contraception include:

• Condoms
• Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal
• Progestogen-only hormonal contraception associated with inhibition of ovulation oral, injectable or implantable
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
• Vasectomy (or vasectomised partner)
• Sexual abstinence. [Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), and spermicides only are not acceptable methods of contraception.]
• Male participants must not donate sperm until 30 days after receiving the study medication.
• Participants taking non-prescription/prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety
• Willingness to refrain from driving, cycling, or operating heavy machinery, until the following morning or a restful sleep has occurred, whichever is later.
• Willingness to refrain from drinking alcohol for 3 days before the infusion visit and one day before any of the other visits throughout the study.

Exclusion Criteria

• The participant may not enter the study if ANY of the following apply:
• History of /or current DSM-5 bipolar disorder, schizophrenia or emotionally unstable personality disorder [co-morbid anxiety disorders (including agoraphobia, generalized anxiety disorder, social anxiety disorder and panic disorder) and Posttraumatic Stress Disorder (PTSD) are allowed]
• Participants who fulfil current criteria for other comorbid disorders may still be entered into the study, if, in the opinion of the Investigator, the psychiatric diagnosis will not compromise safety or affect data quality
• Diagnosis of a major cognitive disorder or evidence of cognitive impairment
• Clinically significant risk of suicide
• Participants undergoing or who have undergone electroconvulsive therapy for the treatment of the current episode of depression
• Substance or alcohol use disorder over the past 6 months
• Regular alcohol consumption of more than 21 units a week or excessive alcohol consumption up to three days before any of the in-person study visits or inability to abstain from alcohol for more than 3 days
• Moderate cigarette use (> 10 cigarettes per day)
• History of, or current general medical conditions that in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study
• Current pregnancy (as determined by urine pregnancy test), breastfeeding, planning a pregnancy, or unwillingness to practice birth control during the course of the study
• Clinically significant abnormalities of laboratory tests, physical examination, or ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
• Current or past history of heart rhythm disorders
• Clinically significant untreated hypertension
• Any contraindication to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more
• Previous participation in a study using the same, or similar, emotional processing tasks in the last three months
• Previous lifetime use of ketamine or phencyclidine
• Participant with planned medical treatment within the study period that might interfere with the study procedures
• Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Catherine Harmer, DPhil

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Locations

Department of Psychiatry, University of Oxford

Oxford, , United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Sara Costi, MD

Role: CONTACT

sara.costi@psych.ox.ac.uk

01865 618303

Facility Contacts

Catherine J Harmer, DPhil

Role: primary

catherine.harmer@psych.ox.ac.uk

+44 (0)1865 618326

Other Identifiers

GEMS

Identifier Type: -

Identifier Source: org_study_id